Catheter with laminar flow drug delivery properties

• US 8,641,666 B2
• Filed: 05/16/2007
• Issued: 02/04/2014
• Est. Priority Date: 05/16/2007
• Status: Active Grant

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: El-Nounou, Fozan O., Ludwig, Florian N., Hossainy, Syed F. A., Consigny, Paul
• Primary Examiner(s): Sirmons, Kevin C
• Assistant Examiner(s): GILBERT, ANDREW M
• Application Number:
  US11/749,665
• Publication Number:
  US 20080287911A1
• Time in Patent Office: 2,456 Days
• Field of Search: 604/95.05, 604/103.01, 604/103.02, 604/103.07, 604/103.08, 604/103.09, 604/107, 604/158
• US Class Current: 604/107
• CPC Class Codes: A61M 2025/0004 having two or more concentrically arranged tubes for forming a concentric catheter system
• CPC Class Codes: A61M 2025/0073 Tip designed for influencing the flow or the flow velocity of the fluid, e.g. inserts for twisted or vortex flow general flow characteristics A61M2206/10
• CPC Class Codes: A61M 2206/11 Laminar flow
• CPC Class Codes: A61M 25/0082 Catheter tip comprising a tool
• CPC Class Codes: A61M 25/01 Introducing, guiding, advancing, emplacing or holding catheters A61M25/10 takes precedence

Abstract

Catheters with laminar flow bioactive agent delivery properties and methods of using for treating or preventing vascular disease are disclosed.

Claims

1. A catheter comprising:

an elongate tubular member comprising a proximal end, a distal end and a lumen extending from the proximal end to the distal end; and

an elongate cylindrical member disposed at least partially within the lumen of the elongate tubular member and having a proximal end, a distal end and a delivery assembly extending from the distal end, wherein the delivery assembly comprises a flared conical shaped member, and wherein a fluid delivery lumen within the elongate cylindrical member opens to a plurality of tubular fluid delivery channels disposed within the flared conical shaped member,

wherein the tubular fluid delivery channels are embedded within a wall of the flared conical shaped member, each of the tubular fluid delivery channels terminate at a fluid exit opening, each fluid exit opening is formed in the wall of the flared conical shaped member and discharges liquid received from the fluid delivery lumen out of the fluid exit opening to deliver a bioactive agent to a patient, and each fluid exit opening faces in a distal direction away from the distal end of the elongate cylindrical member.

2. The catheter according to claim 1, wherein the elongate cylindrical member is extendable and retractable such that in its retracted position the delivery assembly is disposed within the lumen of the tubular member and in its extended position the delivery assembly extends beyond the distal end of the tubular member.

3. The catheter according to claim 1, wherein the lumen of the elongate cylindrical member extends from the proximal end to the distal end of the elongate cylindrical member.

4. The catheter according to claim 2, wherein each of the plurality of tubular fluid delivery channels radiates outward from the distal end of the elongate cylindrical member when the elongate cylindrical member is in its extended position.

5. The catheter according to claim 2, wherein the delivery assembly comprises a shape memory polymer or a shape memory metal.

6. The catheter according claim 1, wherein the wall of the flared conical shaped member forms a circle, as viewed in line with a longitudinal axis of the elongate tubular member, when the elongate cylindrical member is in an extended position beyond the distal end of the tubular member.

7. A method for treating or preventing a vascular disease comprising:

inserting a catheter into a blood vessel of a patient; and

introducing a bioactive agent formulation into the blood vessel through the catheter,

wherein the catheter comprises;

an elongate tubular member comprising a proximal end, a distal end and a lumen extending from the proximal end to the distal end; and

an elongate cylindrical member disposed at least partially within the lumen of the elongate tubular member and having a proximal end, a distal end and a delivery assembly extending from the distal end, wherein the delivery assembly comprises a lumen within the elongate cylindrical member that opens to a plurality of tubular channels which cumulatively release the bioactive agent formulation into the blood vessel, wherein the tubular channels are embedded within a wall of a flared conical shaped member of the delivery assembly, and outlets of the tubular channels, from which the bioactive agent formulation is released, are formed in the wall and face in a distal direction away from the distal end of the elongate tubular member.

8. The method according to claim 7, wherein the viscosity of the bioactive agent formulation is modified by an excipient comprising a polymer, a protein, a sugar or an alcohol.

9. The method according to claim 7, wherein introducing the bioactive agent formulation into the blood vessel of a patient does not impede the flow of blood through the vessel.

10. The method according to claim 7, wherein the bioactive agent formulation comprises a corticosteroid, everolimus, zotarolimus, sirolimus, a sirolimus derivative, paclitaxel, a bisphosphonate, ApoA1, a mutated ApoA1, ApoA1 milano, an ApoA1 mimetic peptide, an ABC A1 agonist, an anti-inflammatory agent, an anti-proliferative agent, an anti-angiogenic agent, an antifibrotic agent, a profibrotic agent, an antithrombotic agent, a matrix metalloproteinase inhibitor or a tissue inhibitor of metalloproteinase.

11. The method according to claim 7, wherein the bioactive agent formulation has a viscosity higher than that of blood and no greater than 500 centipoise.

12. The method of claim 11, wherein the viscosity of the bioactive agent formulation is no greater than 50 centipoise.

13. The method of claim 7, wherein the tubular channels are adjacent to an atherosclerotic lesion when the bioactive agent formulation is released from the tubular channels.

14. The method of claim 7, wherein the tubular channels are adjacent to a site of vulnerable plaque when the bioactive agent formulation is released from the tubular channels.

15. The method of claim 7, wherein when the bioactive agent formulation is released from the tubular channels, the tubular channels are adjacent to a site where angioplasty or another surgical procedure was previously performed.